Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

About this update from Anaptysbio, Inc.

[{"type":"text","content":"WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in New England Journal of Medicine (NEJM) Evidence1.","length":299,"tagName":"p"},{"type":"image","alt":"Vanda Logo (PRNewsfoto/Vanda Pharmaceuticals Inc.)","displaySize":"","headline":null,"caption":"Vanda Logo (PRNewsfoto/Vanda Pharmaceuticals Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":260,"url":"https://media.zenfs.com/en/prnewswire.com/743d2f4492e0b465012535111f8b6bc6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Gg3NnHbVhI0MEomtkVbguw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ1OA--/https://media.zenfs.com/en/prnewswire.com/743d2f4492e0b465012535111f8b6bc6","width":400,"height":260}},"href":"https://mma.prnewswire.com/media/2090054/VandaLogo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), submitted to the U.S. Food and Drug Administration (FDA) with a target action date of December 12, 2026.","length":280,"tagName":"p"},{"type":"text","content":"References","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. NEJM Evidence 5, (2026).","length":115,"tagName":"p"}]}],"tagName":"ol","bulletedList":false,"length":115,"olType":"1"},{"type":"text","content":"About Imsidolimab","length":17,"tagName":"p"},{"type":"text","content":"Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is being developed for GPP, a rare orphan indication. Regulatory and patent exclusivity for imsidolimab is expected to extend into the late 2030s. Vanda holds an exclusive global license for the development and commercialization of imsidolimab from AnaptysBio (Nasdaq: ANAB).","length":376,"tagName":"p"},{"type":"text","content":"About Vanda Pharmaceuticals","length":27,"tagName":"p"},{"type":"text","content":"Vanda is a leading global biopharmaceutical company focused on the development and commer...

More updates from Anaptysbio, Inc.